Development of antioxidant COX-2 inhibitors as radioprotective agents for radiation therapy—a hypothesis-driven review

Antioxidants

Volumn 5, Issue 2, 2016, Pages

  Laube, Markus ^a   Kniess, Torsten ^a   Pietzsch, Jens ^a,b  

^a INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

COX 2 inhibitors (COXIBs); Cyclooxygenases; Nonsteroidal anti inflammatory drugs (NSAIDS); Normal tissue; Oxidative stress; Radiation induced vascular dysfunction; Radioprotection; Radiosensitization; Reactive oxygen nitrogen species; Tumor models

Indexed keywords

EID: 85010469550     PISSN: None     EISSN: 20763921     Source Type: Journal    
DOI: 10.3390/antiox5020014     Document Type: Review

References (229)

1. Adam, A.; Kenny, L.M. Interventional oncology in multidisciplinary cancer treatment in the 21st century. Nat. Rev. Clin. Oncol. 2015, 12, 105–113.
2. Hubenak, J.R.; Zhang, Q.; Branch, C.D.; Kronowitz, S.J. Mechanisms of injury to normal tissue after radiotherapy: A review. Plast. Reconstr. Surg. 2014, 133, 49e–56e.
3. Liauw, S.L.; Connell, P.P.; Weichselbaum, R.R. New paradigms and future challenges in radiation oncology: An update of biological targets and technology. Sci. Transl. Med. 2013, 5.
4. Johnke, R.M.; Sattler, J.A.; Allison, R.R. Radioprotective agents for radiation therapy: Future trends. Future Oncol. 2014, 10, 2345–2357.
5. Vasin, M.V. Comments on the mechanisms of action of radiation protective agents: Basis components and their polyvalence. SpringerPlus 2014, 3, 414.
6. Weiss, J.F.; Landauer, M.R. History and development of radiation-protective agents. Int. J. Radiat. Biol. 2009, 85, 539–573.
7. Kamran, M.Z.; Ranjan, A.; Kaur, N.; Sur, S.; Tandon, V. Radioprotective agents: Strategies and translational advances. Med. Res. Rev. 2016.
8. Radvansky, L.J.; Pace, M.B.; Siddiqui, A. Prevention and management of radiation-induced dermatitis, mucositis, and xerostomia. Am. J. Health Syst. Pharm. 2013, 70, 1025–1032.
9. Hosseinimehr, S.J. Trends in the development of radioprotective agents. Drug Discov. Today 2007, 12, 794–805.
10. Zhao, W.; Robbins, M.E. Inflammation and chronic oxidative stress in radiation-induced late normal tissue injury: Therapeutic implications. Curr. Med. Chem. 2009, 16, 130–143.
11. Hei, T.K.; Zhou, H.; Ivanov, V.N.; Hong, M.; Lieberman, H.B.; Brenner, D.J.; Amundson, S.A.; Geard, C.R. Mechanism of radiation-induced bystander effects: A unifying model. J. Pharm. Pharmacol. 2008, 60, 943–950.
12. Nikitaki, Z.; Mavragani, I.V.; Laskaratou, D.A.; Gika, V.; Moskvin, V.P.; Theofilatos, K.; Vougas, K.; Stewart, R.D.; Georgakilas, A.G. Systemic mechanisms and effects of ionizing radiation: A new “old” paradigm of how the bystanders and distant can become the players. Semin. Cancer Biol. 2016.
13. Georgakilas, A.G.; Pavlopoulou, A.; Louka, M.; Nikitaki, Z.; Vorgias, C.E.; Bagos, P.G.; Michalopoulos, I. Emerging molecular networks common in ionizing radiation, immune and inflammatory responses by employing bioinformatics approaches. Cancer Lett. 2015, 368, 164–172.
14. Basavaraju, S.R.; Easterly, C.E. Pathophysiological effects of radiation on atherosclerosis development and progression, and the incidence of cardiovascular complications. Med. Phys. 2002, 29, 2391–2403.
15. Stewart, F.A.; Hoving, S.; Russell, N.S. Vascular damage as an underlying mechanism of cardiac and cerebral toxicity in irradiated cancer patients. Radiat. Res. 2010, 174, 865–869.
16. Koukourakis, M.I. Radiation damage and radioprotectants: New concepts in the era of molecular medicine. Br. J. Radiol. 2012, 85, 313–330.
17. Denham, J.W.; Hauer-Jensen, M. The radiotherapeutic injury—A complex “wound”. Radiother. Oncol. 2002, 63, 129–145.
18. Di Maggio, F.M.; Minafra, L.; Forte, G.I.; Cammarata, F.P.; Lio, D.; Messa, C.; Gilardi, M.C.; Bravata, V. Portrait of inflammatory response to ionizing radiation treatment. J. Inflamm. 2015, 12, 14.
19. Schaue, D.; Kachikwu, E.L.; McBride, W.H. Cytokines in radiobiological responses: A review. Radiat. Res. 2012, 178, 505–523.
20. Slezak, J.; Kura, B.; Ravingerova, T.; Tribulova, N.; Okruhlicova, L.; Barancik, M. Mechanisms of cardiac radiation injury and potential preventive approaches. Can. J. Physiol. Pharmacol. 2015, 93, 737–753.
21. Hei, T.K.; Zhou, H.; Chai, Y.; Ponnaiya, B.; Ivanov, V.N. Radiation induced non-targeted response: Mechanism and potential clinical implications. Curr. Mol. Pharmacol. 2011, 4, 96–105.
22. Davis, J.N.; McCabe, M.T.; Hayward, S.W.; Park, J.M.; Day, M.L. Disruption of Rb/E2F pathway results in increased cyclooxygenase-2 expression and activity in prostate epithelial cells. Cancer Res. 2005, 65, 3633–3642.
23. Bruning, U.; Fitzpatrick, S.F.; Frank, T.; Birtwistle, M.; Taylor, C.T.; Cheong, A. NFkappaB and HIF display synergistic behaviour during hypoxic inflammation. Cell. Mol. Life Sci. 2012, 69, 1319–1329.
24. Michalowski, A.S. On radiation-damage to normal-tissues and its treatment. 2. Antiinflammatory drugs. Acta Oncol. 1994, 33, 139–157.
25. Fajardo, L.F.L.G. Ionizing radiation and the endothelium. In Late Effects of Cancer Treatment on Normal Tissues; Rubin, P., Constine, L.S., Marks, L.B., Okunieff, P., Eds.; Springer: Berlin, Heidelberg, Germany, 2008; p. 19.
26. Citrin, D.; Cotrim, A.P.; Hyodo, F.; Baum, B.J.; Krishna, M.C.; Mitchell, J.B. Radioprotectors and mitigators of radiation-induced normal tissue injury. Oncologist 2010, 15, 360–371.
27. Weiss, J.F.; Landauer, M.R. Radioprotection by antioxidants. Ann. N. Y. Acad. Sci. 2000, 899, 44–60.
28. Vadhan-Raj, S.; Goldberg, J.D.; Perales, M.A.; Berger, D.P.; van den Brink, M.R. Clinical applications of palifermin: Amelioration of oral mucositis and other potential indications. J. Cell. Mol. Med. 2013, 17, 1371–1384.
29. Komaki, R.; Chang, J.; Liao, Z.; Cox, J.D.; Mason, K.; Milas, L. Radioprotectors and chemoprotectors in the management of lung cancer. In Advances in Radiation Oncology in Lung Cancer; Jeremic, B., Ed.; Springer: Berlin, Heidelberg, Germany, 2005; p. 123.
30. Ullm, S.; Laube, M.; Bechmann, N.; Kniess, T.; Pietzsch, J. Organotypical vascular model for characterization of radioprotective compounds: Studies on antioxidant 2,3-diaryl-substituted indole-based cyclooxygenase-2 inhibitors. Clin. Hemorheol. Microcirc. 2014, 58, 281–295.
31. Pietzsch, J.; Laube, M.; Bechmann, N.; Pietzsch, F.J.; Kniess, T. Protective effects of 2,3-diaryl-substituted indole-based cyclooxygenase-2 inhibitors on oxidative modification of human low density lipoproteins in vitro. Clin. Hemorheol. Microcirc. 2015, 61, 615–632.
32. Fu, J.Y.; Masferrer, J.L.; Seibert, K.; Raz, A.; Needleman, P. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J. Biol. Chem. 1990, 265, 16737–16740.
33. De Vries, E.F. Imaging of cyclooxygenase-2 (COX-2) expression: Potential use in diagnosis and drug evaluation. Curr. Pharm. Des. 2006, 12, 3847–3856.
34. Hawkey, C.J. COX-2 chronology. Gut 2005, 54, 1509–1514.
35. Laube, M.; Kniess, T.; Pietzsch, J. Radiolabeled COX-2 inhibitors for non-invasive visualization of COX-2 expression and activity—A critical update. Molecules 2013, 18, 6311–6355.
36. Moore, A.H.; Olschowka, J.A.; Williams, J.P.; Paige, S.L.; O’Banion, M.K. Radiation-induced edema is dependent on cyclooxygenase 2 activity in mouse brain. Radiat. Res. 2004, 161, 153–160.
37. Sobolewski, C.; Cerella, C.; Dicato, M.; Ghibelli, L.; Diederich, M. The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies. Int. J. Cell. Biol. 2010, 2010.
38. Simmons, D.L.; Botting, R.M.; Hla, T. Cyclooxygenase isozymes: The biology of prostaglandin synthesis and inhibition. Pharmacol. Rev. 2004, 56, 387–437.
39. Choy, H.; Milas, L. Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: A rational advance? J. Natl. Cancer Inst. 2003, 95, 1440–1452.
40. 2+-toxicity in primary cortical culture. Mol. Pharmacol. 2004, 66, 368–376.
41. Im, J.Y.; Kim, D.; Paik, S.G.; Han, P.L. Cyclooxygenase-2-dependent neuronal death proceeds via superoxide anion generation. Free Radic. Biol. Med. 2006, 41, 960–972.
42. Van der Donk, W.A.; Tsai, A.-L.; Kulmacz, R.J. The cyclooxygenase reaction mechanism. Biochemistry 2002, 41, 15451–15458.
43. Rouzer, C.A.; Marnett, L.J. Cyclooxygenases: Structural and functional insights. J. Lipid Res. 2009, 50, S29–S34.
44. Zarghi, A.; Arfaei, S. Selective COX-2 inhibitors: A review of their structure-activity relationships. Iran. J. Pharm. Res. 2011, 10, 655–683.
45. Rao, R.; Knaus, E.E. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): Cyclooxygenase (COX) inhibition and beyond. J. Pharm. Pharmacet. Sci. 2008, 11, 81s–110s.
46. Blobaum, A.L.; Marnett, L.J. Structural and functional basis of cyclooxygenase inhibition. J. Med. Chem. 2007, 50, 1425–1441.
47. Walter, M.F.; Jacob, R.F.; Day, C.A.; Dahlborg, R.; Weng, Y.; Mason, R.P. Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: Comparison to sulfonamide COX-2 inhibitors and NSAIDs. Atherosclerosis 2004, 177, 235–243.
48. Reddy, L.R.; Corey, E.J. Facile air oxidation of the conjugate base of rofecoxib (Vioxx™), a possible contributor to chronic human toxicity. Tetrahedron Lett. 2005, 46, 927–929.
49. Mason, R.P.; Walter, M.F.; McNulty, H.P.; Lockwood, S.F.; Byun, J.; Day, C.A.; Jacob, R.F. Rofecoxib increases susceptibility of human LDL and membrane lipids to oxidative damage: A mechanism of cardiotoxicity. J. Cardiovasc. Pharmacol. 2006, 47 (Suppl. 1), S7–S14.
50. Marnett, L.J. The COXIB experience: A look in the rearview mirror. Annu. Rev. Pharmacol. Toxicol. 2009, 49, 265–290.
51. Peters, J.; Nel, D.; Adam, S. Reaching and influencing consumers in the prescription medicine market. Mark. Intell. Plan. 2009, 27, 909–925.
52. Milne, G.L.; Yin, H.; Hardy, K.D.; Davies, S.S.; Roberts, L.J., 2nd. Isoprostane generation and function. Chem. Rev. 2011, 111, 5973–5996.
53. Praticò, D.; Lawson, J.A.; Rokach, J.; FitzGerald, G.A. The isoprostanes in biology and medicine. Trends Endocrinol. Metab. 2001, 12, 243–247.
54. Praticò, D. Prostanoid and isoprostanoid pathways in atherogenesis. Atherosclerosis 2008, 201, 8–16.
55. Montuschi, P.; Barnes, P.J.; Roberts, L.J., 2nd. Isoprostanes: Markers and mediators of oxidative stress. FASEB J. 2004, 18, 1791–1800.
56. Saha, D.; Choy, H. Potential for combined modality therapy of cyclooxygenase inhibitors and radiation. Prog. Exp. Tumor Res. 2003, 37, 193–209.
57. Furuta, Y.; Hunter, N.; Barkley, T., Jr.; Hall, E.; Milas, L. Increase in radioresponse of murine tumors by treatment with indomethacin. Cancer Res. 1988, 48, 3008–3013.
58. Davis, T.W.; Hunter, N.; Trifan, O.C.; Milas, L.; Masferrer, J.L. COX-2 inhibitors as radio sensitizing agents for cancer therapy. Am. J. Clin. Oncol. 2003, 26, S58–S61.
59. Crokart, N.; Radermacher, K.; Jordan, B.F.; Baudelet, C.; Cron, G.O.; Gregoire, V.; Beghein, N.; Bouzin, C.; Feron, O.; Gallez, B. Tumor radiosensitization by anti-inflammatory drugs: Evidence for a new mechanism involving the oxygen effect. Cancer Res. 2005, 65, 7911–7916.
60. Kishi, K.; Petersen, S.; Petersen, C.; Hunter, N.; Mason, K.; Masferrer, J.L.; Tofilon, P.J.; Milas, L. Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res. 2000, 60, 1326–1331.
61. Milas, L.; Kishi, K.; Hunter, N.; Mason, K.; Masferrer, J.L.; Tofilon, P.J. Enhancement of tumor response to γ-radiation by an inhibitor of cyclooxygenase-2 enzyme. J. Natl. Cancer Inst. 1999, 91, 1501–1504.
62. Petersen, C.; Petersen, S.; Milas, L.; Lang, F.F.; Tofilon, P.J. Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor. Clin. Cancer Res. 2000, 6, 2513–2520.
63. Kang, K.B.; Wang, T.T.; Woon, C.T.; Cheah, E.S.; Moore, X.L.; Zhu, C.; Wong, M.C. Enhancement of glioblastoma radioresponse by a selective COX-2 inhibitor celecoxib: Inhibition of tumor angiogenesis with extensive tumor necrosis. Int. J. Radiat. Oncol. Biol. Phys. 2007, 67, 888–896.
64. Ma, H.I.; Chiou, S.H.; Hueng, D.Y.; Tai, L.K.; Huang, P.I.; Kao, C.L.; Chen, Y.W.; Sytwu, H.K. Celecoxib and radioresistant glioblastoma-derived CD133+ cells: Improvement in radiotherapeutic effects. Laboratory investigation. J. Neurosurg. 2011, 114, 651–662.
65. Wagemakers, M.; van der Wal, G.E.; Cuberes, R.; Álvarez, I.; Andrés, E.M.; Buxens, J.; Vela, J.M.; Moorlag, H.; Mooij, J.J.A.; Molema, G. COX-2 inhibition combined with radiation reduces orthotopic glioma outgrowth by targeting the tumor vasculature. Transl. Oncol. 2009, 2, 1–7.
66. Klenke, F.M.; Abdollahi, A.; Bischof, M.; Gebhard, M.M.; Ewerbeck, V.; Huber, P.E.; Sckell, A. Celecoxib enhances radiation response of secondary bone tumors of a human non-small cell lung cancer via antiangiogenesis in vivo. Strahlenther. Onkol. 2011, 187, 45–51.
67. Kim, B.M.; Won, J.; Maeng, K.A.; Han, Y.S.; Yun, Y.S.; Hong, S.H. Nimesulide, a selective COX-2 inhibitor, acts synergistically with ionizing radiation against A549 human lung cancer cells through the activation of caspase-8 and caspase-3. Int. J. Oncol. 2009, 34, 1467–1473.
68. Sminia, P.; Kuipers, G.; Geldof, A.; Lafleur, V.; Slotman, B. COX-2 inhibitors act as radiosensitizer in tumor treatment. Biomed. Pharmacother. 2005, 59, S272–S275.
69. Davis, T.W.; O’Neal, J.M.; Pagel, M.D.; Zweifel, B.S.; Mehta, P.P.; Heuvelman, D.M.; Masferrer, J.L. Synergy between celecoxib and radiotherapy results from inhibition of cyclooxygenase-2-derived prostaglandin E2, a survival factor for tumor and associated vasculature. Cancer Res. 2004, 64, 279–285.
70. Wang, A.H.; Tian, X.Y.; Yu, J.J.; Mi, J.Q.; Liu, H.; Wang, R.F. Celecoxib radiosensitizes the human cervical cancer HeLa cell line via a mechanism dependent on reduced cyclo-oxygenase-2 and vascular endothelial growth factor C expression. J. Int. Med. Res. 2012, 40, 56–66.
71. Raju, U.; Ariga, H.; Dittmann, K.; Nakata, E.; Ang, K.K.; Milas, L. Inhibition of DNA repair as a mechanism of enhanced radioresponse of head and neck carcinoma cells by a selective cyclooxygenase-2 inhibitor, celecoxib. Int. J. Radiat. Oncol. 2005, 63, 520–528.
72. Che, S.M.; Zhang, X.Z.; Hou, L.; Song, T.B. Cyclooxygenase-2 inhibitor NS398 enhances radiosensitivity of radioresistant esophageal cancer cells by inhibiting AKT activation and inducing apoptosis. Cancer Investig. 2010, 28, 679–688.
73. Dittmann, K.H.; Mayer, C.; Ohneseit, P.A.; Raju, U.; Andratschke, N.H.; Milas, L.; Rodemann, H.P. Celecoxib induced tumor cell radiosensitization by inhibiting radiation induced nuclear EGFR transport and DNA-repair: A COX-2 independent mechanism. Int. J. Radiat. Oncol. Biol. Phys. 2008, 70, 203–212.
74. Ohneseit, P.A.; Krebiehl, G.; Dittmann, K.; Kehlbach, R.; Rodemann, H.P. Inhibition of cyclooxygenase-2 activity by celecoxib does not lead to radiosensitization of human prostate cancer cells in vitro. Radiother. Oncol. 2007, 82, 229–238.
75. Steinauer, K.K.; Gibbs, I.; Ning, S.; French, J.N.; Armstrong, J.; Knox, S.J. Radiation induces upregulation of cyclooxygenase-2 (COX-2) protein in PC-3 cells. Int. J. Radiat. Oncol. Biol. Phys. 2000, 48, 325–328.
76. Czembirek, C.; Eder-Czembirek, C.; Erovic, B.; Turhani, D.; Spittler, A.; Selzer, E.; Pötter, R.; Thurnher, D. The cyclooxygenase-2 inhibitor nimesulide, a nonsteroidal analgesic, decreases the effect of radiation therapy in head-and-neck cancer cells. Strahlenther. Onkol. 2009, 185, 310–317.
77. Nakata, E.; Mason, K.A.; Hunter, N.; Husain, A.; Raju, U.; Liao, Z.; Ang, K.K.; Milas, L. Potentiation of tumor response to radiation or chemoradiation by selective cyclooxygenase-2 enzyme inhibitors. Int. J. Radiat. Oncol. Biol. Phys. 2004, 58, 369–375.
78. Handrick, R.; Ganswindt, U.; Faltin, H.; Goecke, B.; Daniel, P.T.; Budach, W.; Belka, C.; Jendrossek, V. Combined action of celecoxib and ionizing radiation in prostate cancer cells is independent of pro-apoptotic bax. Radiother. Oncol. 2009, 90, 413–421.
79. Suzuki, K.; Gerelchuluun, A.; Hong, Z.S.; Sun, L.; Zenkoh, J.; Moritake, T.; Tsuboi, K. Celecoxib enhances radiosensitivity of hypoxic glioblastoma cells through endoplasmic reticulum stress. Neuro-Oncology 2013, 15, 1186–1199.
80. Raju, U.; Nakata, E.; Yang, P.Y.; Newman, R.A.; Ang, K.K.; Milas, L. In vitro enhancement of tumor cell radiosensitivity by a selective inhibitor of cyclooxygenase-2 enzyme: Mechanistic considerations. Int. J. Radiat. Oncol. 2002, 54, 886–894.
81. Bijnsdorp, I.V.; van den Berg, J.; Kuipers, G.K.; Wedekind, L.E.; Slotman, B.J.; van Rijn, J.; Lafleur, M.V.M.; Sminia, P. Radiosensitizing potential of the selective cyclooygenase-2 (COX-2) inhibitor meloxicam on human glioma cells. J. Neuro-Oncol. 2007, 85, 25–31.
82. Karim, A.; McCarthy, K.; Jawahar, A.; Smith, D.; Willis, B.; Nanda, A. Differential cyclooxygenase-2 enzyme expression in radiosensitive versus radioresistant glioblastoma multiforme cell lines. Anticancer Res. 2005, 25, 675–680.
83. Ganswindt, U.; Budach, W.; Jendrossek, V.; Becker, G.; Bamberg, M.; Belka, C. Combination of celecoxib with percutaneous radiotherapy in patients with localised prostate cancer—A phase I study. Radiat. Oncol. 2006, 1.
84. Rich, T.A.; Shepard, R. COX-2 inhibitors as radiation sensitizers for upper GI tract cancers: Esophagus, stomach, and pancreas. Am. J. Clin. Oncol. 2003, 26, S110–S113.
85. Debucquoy, A.; Roels, S.; Goethals, L.; Libbrecht, L.; Cutsem, E.V.; Geboes, K.; Penninckx, F.; D’Hoore, A.; McBride, W.H.; Haustermans, K. Double blind randomized phase ii study with radiation + 5-fluorouracil ˘ celecoxib for resectable rectal cancer. Radiother. Oncol. 2009, 93, 273–278.
86. Wang, L.W.; Hsiao, C.F.; Chen, W.T.; Lee, H.H.; Lin, T.C.; Chen, H.C.; Chen, H.H.; Chien, C.R.; Lin, T.Y.; Liu, T.W. Celecoxib plus chemoradiotherapy for locally advanced rectal cancer: A phase II tcog study. J. Surg. Oncol. 2014, 109, 580–585.
87. Kao, J.; Genden, E.M.; Chen, C.T.; Rivera, M.; Tong, C.C.; Misiukiewicz, K.; Gupta, V.; Gurudutt, V.; Teng, M.; Packer, S.H. Phase 1 trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck cancer. Cancer 2011, 117, 3173–3181.
88. Jalalabadi, Y.; Shirazi, A.; Ghavam-Nasiri, M.-R.; Davood, A.; Sardari, D. The role of celecoxib as a COX-2 inhibitor increasing the radiosensitivity of tumor tissue. Br. J. Med. Med. Res. 2015, 8, 123–139.
89. Hofer, M.; Pospisil, M.; Hoferova, Z.; Weiterova, L.; Komurkova, D. Stimulatory action of cyclooxygenase inhibitors on hematopoiesis: A review. Molecules 2012, 17, 5615–5625.
90. Rezvani, M. Treatment of radiation-induced normal tissue lesions. Iran. J. Radiat. Res. 2003, 1, 63–78.
91. Lalla, R.V.; Schubert, M.M.; Bensadoun, R.J.; Keefe, D. Anti-inflammatory agents in the management of alimentary mucositis. Support. Care Cancer 2006, 14, 558–565.
92. Lee, T.K.; Stupans, I. Radioprotection: The non-steroidal anti-inflammatory drugs (NSAIDs) and prostaglandins. J. Pharm. Pharmacol. 2002, 54, 1435–1445.
93. Verheij, M.; Stewart, F.A.; Oussoren, Y.; Weening, J.J.; Dewit, L. Amelioration of radiation nephropathy by acetylsalicylic acid. Int. J. Radiat. Biol. 1995, 67, 587–596.
94. Van Kleef, E.M.; Te Poele, J.A.M.; Oussoren, Y.G.; van der Wal, A.; Dewi, L.G.H.; Stewartab, F.A. Influence of acetylsalicylic acid on development of radiation-induced nephropathy. Int. J. Radiat. Biol. 2000, 76, 1565–1573.
95. Demirel, C.; Kilciksiz, S.C.; Gurgul, S.; Erdal, N.; Yigit, S.; Tamer, L.; Ayaz, L. Inhibition of radiation-induced oxidative damage in the lung tissue: May acetylsalicylic acid have a positive role? Inflammation 2015, 39, 158–165.
96. Mennie, A.T.; Dalley, V.M.; Dinneen, L.C.; Collier, H.O.J. Treatment of radiation-induced gastrointestinal distress with acetylsalicylate. Lancet 1975, 2, 942–943.
97. Ludgate, C.M. Preliminary report: Acetylsalicylic acid therapy in the treatment of complications following abdominal radiation. J. Can. Assoc. Radiol. 1985, 36, 138–140.
98. Olivotto, I.A.; Kim-Sing, C.; Bajdik, C.D.; Trevisan, C.H.; Ludgate, C.M.; Weir, L.M.; Jackson, S.M.; Basco, V.E. Effect of acetylsalicylic acid on radiation and cosmetic results after conservative surgery for early breast cancer: A randomized trial. Radiother. Oncol. 1996, 41, 1–6.
99. 2. Inflammopharmacology 1995, 3, 251–257.
100. Sorenson, J.R. Bis(3,5-diisopropylsalicylato)copper(II), a potent radioprotectant with superoxide dismutase mimetic activity. J. Med. Chem. 1984, 27, 1747–1749.
101. Borowska, A.; Sierakowski, S.; Mackowiak, J.; Wisniewski, K. A prostaglandin-like activity in small intestine and postirradiation gastrointestional syndrome. Experientia 1979, 35, 1368–1370.
102. Tochner, Z.; Barnes, M.; Mitchell, J.B.; Orr, K.; Glatstein, E.; Russo, A. Protection by indomethacin against acute radiation esophagitis. Digestion 1990, 47, 81–87.
103. Rose, P.G.; Halter, S.A.; Su, C.M. The effect of indomethacin on acute radiation induced gastrointestinal injury: A morphologic study. J. Surg. Oncol. 1992, 49, 231–238.
104. Carpenter, D.O.; Briggs, D.B.; Knox, A.P.; Strominger, N.L. Radiation-induced emesis in the dog: Effects of lesions and drugs. Radiat. Res. 1986, 108, 307–316.
105. Northway, M.G.; Libshitz, H.I.; Osborne, B.M.; Feldman, M.S.; Mamel, J.J.; West, J.H.; Szwarc, I.A. Radiation esophagitis in the opossum: Radioprotection with indomethacin. Gastroenterology 1980, 78, 883–892.
106. Northway, M.G.; Scobey, M.W.; Geisinger, K.R. Radiation proctitis in the rat: Sequential changes and effects of anti-inflammatory agents. Cancer 1988, 62, 1962–1969.
107. Goldberg, R.I. Protection of irradiated parotid by prostaglandin synthesis inhibitors. J. Am. Dent. Assoc. 1986, 112, 179–181.
108. Kandasamy, S.B.; Hunt, W.A. Involvement of prostaglandins and histamine in radiation-induced temperature responses in rats. Radiat. Res. 1990, 121, 84–90.
109. Kandasamy, S.B.; Hunt, W.A.; Mickley, G.A. Implication of prostaglandins and histamine H1 and H2 receptors in radiation-induced temperature responses of rats. Radiat. Res. 1988, 114, 42–53.
110. Song, C.W.; Drescher, J.J.; Tabachnick, J. Effect of anti-inflammatory compounds on beta-irradiation-induced increase in vascular peremeability. Radiat. Res. 1968, 34, 616–625.
111. Nicolopoulos, N.; Mantidis, A.; Stathopoulos, E.; Papaodysseas, S.; Kouvaris, J.; Varveris, H.; Papavasiliou, C. Prophylactic administration of indomethacin for irradiation esophagitis. Radiother. Oncol. 1985, 3, 23–25.
112. Pillsbury, H.C., 3rd; Webster, W.P.; Rosenman, J. Prostaglandin inhibitor and radiotherapy in advanced head and neck cancers. Arch. Otolaryngol. Head Neck Surg. 1986, 112, 552–553.
113. Bito, L.Z.; Klein, E.M. The role of the arachidonic acid cascade in the species-specific X-ray-induced inflammation of the rabbit eye. Investig. Ophthalmol. Vis. Sci. 1982, 22, 579–587.
114. Stokman, M.A.; Spijkervet, F.K.; Burlage, F.R.; Roodenburg, J.L. Clinical effects of flurbiprofen tooth patch on radiation-induced oral mucositis. A pilot study. Support. Care Cancer 2005, 13, 42–48.
115. Kozubik, A.; Hofmanova, J.; Pospisil, M.; Netikova, J.; Hola, J.; Lojek, A. Effects of drugs inhibiting prostaglandin or leukotriene biosynthesis on postirradiation hematopoiesis in mouse. Int. J. Radiat. Biol. 1994, 65, 369–377.
116. Hofer, M.; Pospisil, M.; Tkadlecek, L.; Viklicka, S.; Pipalova, I.; Hola, J. Low survival of mice following lethal gamma-irradiation after administration of inhibitors of prostaglandin synthesis. Physiol. Res. 1992, 41, 157–161.
117. Floersheim, G.L. Allopurinol, indomethacin and riboflavin enhance radiation lethality in mice. Radiat. Res. 1994, 139, 240–247.
118. Juchelkova, L.; Hofer, M.; Pospisil, M.; Pipalova, I. Radioprotective effects of flurbiprofen and its nitroderivative. Physiol. Res. 1998, 47, 73–80.
119. Hofer, M.; Pospisil, M.; Znojil, V.; Hola, J.; Vacek, A.; Weiterova, L.; Streitova, D.; Kozubik, A. Meloxicam, a cyclooxygenase 2 inhibitor, supports hematopoietic recovery in gamma-irradiated mice. Radiat. Res. 2006, 166, 556–560.
120. Hofer, M.; Pospisil, M.; Dusek, L.; Hoferova, Z.; Weiterova, L. A single dose of an inhibitor of cyclooxygenase 2, meloxicam, administered shortly after irradiation increases survival of lethally irradiated mice. Radiat. Res. 2011, 176, 269–272.
121. 3 receptor agonist. Cent. Eur. J. Biol. 2014, 9, 642–646.
122. Fedorocko, P.; Mackova, N.O. Combined modality radioprotection: Enhancement of survival and hematopoietic recovery in gamma-irradiated mice by the joint use of liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) and indomethacin. Int. J. Immunopharmacol. 1996, 18, 329–337.
123. Fedorocko, P.; Mackova, O. Radioprotective effects of combination broncho-vaxom, a macrophage activator, and indomethacin, an inhibitor of prostaglandin production: Relationship to myelopoiesis. Eur. J. Haematol. 1996, 56, 54–61.
124. Desmarais, G.; Charest, G.; Fortin, D.; Bujold, R.; Mathieu, D.; Paquette, B. Cyclooxygenase-2 inhibitor prevents radiation-enhanced infiltration of F98 glioma cells in brain of fischer rat. Int. J. Radiat. Biol. 2015, 91, 624–633.
125. Kaplan, B.; Cihan, Y.; Orhan, O.; Yilmaz, S.; Akgun, H.; Saraymen, R. COX-2 as inhibitors to protect radiation induced pneumonia. Asian J. Chem. 2009, 21, 6167–6175.
126. Khayyal, M.T.; El-Ghazaly, M.A.; El-Hazek, R.M.; Nada, A.S. The effects of celecoxib, a COX-2 selective inhibitor, on acute inflammation induced in irradiated rats. Inflammopharmacology 2009, 17, 255–266.
127. El-Ghazaly, M.; Nada, A.S.; El-Hazek, R.; Khayyal, M.T. Effect of selective COX-2 inhibitor, celecoxib on adjuvant-induced arthritis model in irradiated rats. Int. J. Radiat. Biol. 2010, 86, 1079–1087.
128. Liang, L.; Hu, D.; Liu, W.; Williams, J.P.; Okunieff, P.; Ding, I. Celecoxib reduces skin damage after radiation: Selective reduction of chemokine and receptor mrna expression in irradiated skin but not in irradiated mammary tumor. Am. J. Clin. Oncol. 2003, 26, S114–S121.
129. Haagen, J.; Krohn, H.; Röllig, S.; Schmidt, M.; Wolfram, K.; Dörr, W. Effect of selective inhibitors of inflammation on oral mucositis: Preclinical studies. Radiother. Oncol. 2009, 92, 472–476.
130. Lalla, R.V.; Choquette, L.E.; Curley, K.F.; Dowsett, R.J.; Feinn, R.S.; Hegde, U.P.; Pilbeam, C.C.; Salner, A.L.; Sonis, S.T.; Peterson, D.E. Randomized double-blind placebo-controlled trial of celecoxib for oral mucositis in patients receiving radiation therapy for head and neck cancer. Oral Oncol. 2014, 50, 1098–1103.
131. Jiao, W.; Kiang, J.G.; Cary, L.; Elliott, T.B.; Pellmar, T.C.; Ledney, G.D. COX-2 inhibitors are contraindicated for treatment of combined injury. Radiat. Res. 2009, 172, 686–697.
132. Paquette, B.; Therriault, H.; Desmarais, G.; Wagner, R.; Royer, R.; Bujold, R. Radiation-enhancement of MDA-MB-231 breast cancer cell invasion prevented by a cyclooxygenase-2 inhibitor. Br. J. Cancer 2011, 105, 534–541.
133. Zhou, H.N.; Ivanov, V.N.; Gillespie, J.; Geard, C.R.; Amundson, S.A.; Brenner, D.J.; Yu, Z.L.; Lieberman, H.B.; Hei, T.K. Mechanism of radiation-induced bystander effect: Role of the cyclooxygenase-2 signaling pathway. Proc. Natl. Acad. Sci. USA 2005, 102, 14641–14646.
134. Du, Y.; Zhang, S.; Wang, Z.; Zhou, W.; Luan, M.; Yang, X.; Chen, N. Induction of apoptosis and cell cycle arrest by NS398 in oral squamous cell carcinoma cells via downregulation of E2 promoter-binding factor-1. Oncol. Rep. 2008, 20, 605–611.
135. Pietzsch, J.; Laube, M.; Pietzsch, F.J.; Bergmann, R.; Kniess, T. Concomitant targeting of cyclooxygenase-2 and oxidant stress pathways for radioprotection of endothelial cells. In Coronary Artery Disease: 2011 Update: From Prevention to Intervention; Medimond s.r.l.: Bologna, Italy, 2011; pp. 107–110.
136. Hu, W.; Guo, Z.; Yi, X.; Guo, C.; Chu, F.; Cheng, G. Discovery of 2-phenyl-3-sulfonylphenyl-indole derivatives as a new class of selective COX-2 inhibitors. Bioorg. Med. Chem. 2003, 11, 5539–5544.
137. Hu, W.; Guo, Z.; Chu, F.; Bai, A.; Yi, X.; Cheng, G.; Li, J. Synthesis and biological evaluation of substituted 2-sulfonyl-phenyl-3-phenyl-indoles: A new series of selective COX-2 inhibitors. Bioorg. Med. Chem. 2003, 11, 1153–1160.
138. Guo, Z.; Cheng, G.; Chu, F. Sulfonyl-Containing 2,3-Diarylindole Compounds, Methods for Making Same, and Methods of Use Thereof. U.S. Patent 2004/58977, 25 March 2004.
139. Kniess, T.; Laube, M.; Bergmann, R.; Sehn, F.; Graf, F.; Steinbach, J.; Wuest, F.; Pietzsch, J. Radiosynthesis of a 18F-labeled 2,3-diarylsubstituted indole via mcmurry coupling for functional characterization of cyclooxygenase-2 (COX-2) in vitro and in vivo. Bioorg. Med. Chem. 2012, 20, 3410–3421.
140. Tondera, C.; Laube, M.; Wimmer, C.; Kniess, T.; Mosch, B.; Grossmann, K.; Pietzsch, J. Visualization of cyclooxygenase-2 using a 2,3-diarylsubstituted indole-based inhibitor and confocal laser induced cryofluorescence microscopy at 20K in melanoma cells in vitro. Biochem. Biophys. Res. Commun. 2013, 430, 301–306.
141. Tondera, C.; Ullm, S.; Laube, M.; Meister, S.; Neuber, C.; Mosch, B.; Kniess, T.; Pietzsch, J. Optical imaging of COX-2: Studies on an autofluorescent 2,3-diaryl-substituted indole-based cyclooxygenase-2 inhibitor. Biochem. Biophys. Res. Commun. 2015, 458, 40–45.
142. Laube, M.; Tondera, C.; Sharma, S.K.; Bechmann, N.; Pietzsch, F.-J.; Pigorsch, A.; Kockerling, M.; Wuest, F.; Pietzsch, J.; Kniess, T. 2,3-Diaryl-substituted indole based COX-2 inhibitors as leads for imaging tracer development. RSC Adv. 2014, 4, 38726–38742.
143. Antosiewicz, J.; Damiani, E.; Jassem, W.; Wozniak, M.; Orena, M.; Greci, L. Influence of structure on the antioxidant activity of indolinic nitroxide radicals. Free Radic. Biol. Med. 1997, 22, 249–255.
144. Suzen, S.; Bozkaya, P.; Coban, T.; Nebiogu, D. Investigation of the in vitro antioxidant behaviour of some 2-phenylindole derivatives: Discussion on possible antioxidant mechanisms and comparison with melatonin. J. Enzyme Inhib. Med. Chem. 2006, 21, 405–411.
145. Pietzsch, J.; Pietzsch, F.J.; Laube, M.; Bergmann, R.; Kniess, T.; Wuest, F. 837 concomitant targeting of cyclooxygenase-2 and oxidant stress pathways for radioprotection of normal vascular tissue. EJC Suppl. 2010, 8.
146. Ullm, S.; Sehn, F.; Laube, M.; Tondera, C.; Bechmann, N.; Mosch, B.; Kniess, T.; Pietzsch, J. Targeting cyclooxygenase-2 and oxidant stress pathways for attenuation of radiation-induced vascular dysfunction. In Proceedings of the 6th European Congress of Pharmacology, Granada, Spain, 17–20 July 2012; Zarzuelo, A., Jimenez, R., Eds.; Medimond S.r.l—Monduzzi Editore International: Pianoro, Italy, 2013; p. 87.
147. Wuest, F.; Kniess, T.; Bergmann, R.; Pietzsch, J. Synthesis and evaluation in vitro and in vivo of a 11C-labeled cyclooxygenase-2 (COX-2) inhibitor. Bioorg. Med. Chem. 2008, 16, 7662–7670.
148. Milne, G.L.; Sanchez, S.C.; Musiek, E.S.; Morrow, J.D. Quantification of F2-isoprostanes as a biomarker of oxidative stress. Nat. Protoc. 2007, 2, 221–226.
149. Laube, M.; Gassner, C.; Sharma, S.K.; Gunther, R.; Pigorsch, A.; Konig, J.; Kockerling, M.; Wuest, F.; Pietzsch, J.; Kniess, T. Diaryl-substituted (dihydro)pyrrolo[3,2,1-hi]indoles, a class of potent COX-2 inhibitors with tricyclic core structure. J. Org. Chem. 2015, 80, 5611–5624.
150. Süzen, S. Antioxidant activities of synthetic indole derivatives and possible activity mechanisms. Top. Heterocycl. Chem. 2007, 11, 145–178.
151. Burnett, B.P.; Bitto, A.; Altavilla, D.; Squadrito, F.; Levy, R.M.; Pillai, L. Flavocoxid inhibits phospholipase A2, peroxidase moieties of the cyclooxygenases (COX), and 5-lipoxygenase, modifies COX-2 gene expression, and acts as an antioxidant. Mediat. Inflamm. 2011, 2011.
152. Magalhaes, L.M.; Segundo, M.A.; Reis, S.; Lima, J.L. Methodological aspects about in vitro evaluation of antioxidant properties. Anal. Chim. Acta 2008, 613, 1–19.
153. Costa, D.; Moutinho, L.; Lima, J.L.; Fernandes, E. Antioxidant activity and inhibition of human neutrophil oxidative burst mediated by arylpropionic acid non-steroidal anti-inflammatory drugs. Biol. Pharm. Bull. 2006, 29, 1659–1670.
154. Twomey, B.M.; Dale, M.M. Cyclooxygenase-independent effects of nonsteroidal anti-inflammatory drugs on the neutrophil respiratory burst. Biochem. Pharmacol. 1992, 43, 413–418.
155. Wasil, M.; Halliwell, B.; Moorhouse, C.P.; Hutchison, D.C.; Baum, H. Biologically-significant scavenging of the myeloperoxidase-derived oxidant hypochlorous acid by some anti-inflammatory drugs. Biochem. Pharmacol. 1987, 36, 3847–3850.
156. Fernandes, E.; Toste, S.A.; Lima, J.L.; Reis, S. The metabolism of sulindac enhances its scavenging activity against reactive oxygen and nitrogen species. Free Radic. Biol. Med. 2003, 35, 1008–1017.
157. Neve, J.; Parij, N.; Moguilevsky, N. Inhibition of the myeloperoxidase chlorinating activity by non-steroidal anti-inflammatory drugs investigated with a human recombinant enzyme. Eur. J. Pharmacol. 2001, 417, 37–43.
158. Van Antwerpen, P.; Nève, J. In vitro comparative assessment of the scavenging activity against three reactive oxygen species of non-steroidal anti-inflammatory drugs from the oxicam and sulfoanilide families. Eur. J. Pharmacol. 2004, 496, 55–61.
159. Facino, R.M.; Carini, M.; Aldini, G. Antioxidant activity of nimesulide and its main metabolites. Drugs 1993, 46 (Suppl. 1), 15–21.
160. Maffei Facino, R.; Carini, M.; Aldini, G.; Saibene, L.; Morelli, R. Differential inhibition of superoxide, hydroxyl and peroxyl radicals by nimesulide and its main metabolite 4-hydroxynimesulide. Arzneimittelforschung 1995, 45, 1102–1109.
161. Nam, T.G.; Nara, S.J.; Zagol-Ikapitte, I.; Cooper, T.; Valgimigli, L.; Oates, J.A.; Porter, N.A.; Boutaud, O.; Pratt, D.A. Pyridine and pyrimidine analogs of acetaminophen as inhibitors of lipid peroxidation and cyclooxygenase and lipoxygenase catalysis. Org. Biomol. Chem. 2009, 7, 5103–5112.
162. Kullich, W.; Fagerer, N.; Schwann, H. Effect of the NSAID nimesulide on the radical scavenger glutathione S-transferase in patients with osteoarthritis of the knee. Curr. Med. Res. Opin. 2007, 23, 1981–1986.
163. Naziroglu, M.; Uguz, A.C.; Gokcimen, A.; Bulbul, M.; Karatopuk, D.U.; Turker, Y.; Cerçi, C. Tenoxicam modulates antioxidant redox system and lipid peroxidation in rat brain. Neurochem. Res. 2008, 33, 1832–1837.
164. Ozgocmen, S.; Ardicoglu, O.; Erdogan, H.; Fadillioglu, E.; Gudul, H. In vivo effect of celecoxib and tenoxicam on oxidant/anti-oxidant status of patients with knee osteoarthritis. Ann. Clin. Lab. Sci. 2005, 35, 137–143.
165. Hiller, K.O.; Hodd, P.L.; Willson, R.L. Antiinflammatory drugs: Protection of a bacterial virus as an in vitro biological measure of free radical activity. Chem. Biol. Interact. 1983, 47, 293–305.
166. Fernandes, E.; Costa, D.; Toste, S.A.; Lima, J.L.; Reis, S. In vitro scavenging activity for reactive oxygen and nitrogen species by nonsteroidal anti-inflammatory indole, pyrrole, and oxazole derivative drugs. Free Radic. Biol. Med. 2004, 37, 1895–1905.
167. Ahmed, S.; Gul, S.; Gul, H.; Zia-Ul-Haq, M.; Ercisli, S. Cyclooxygenase-2 inhibition improves antioxidative defense during experimental hypercholesterolemia. Bosn. J. Basic Med. Sci. 2014, 14, 63–69.
168. Gupta, S.; Sarotra, P.; Aggarwal, R.; Dutta, N.; Agnihotri, N. Role of oxidative stress in celecoxib-induced renal damage in wistar rats. Dig. Dis. Sci. 2007, 52, 3092–3098.
169. Demiryilmaz, I.; Turan, M.I.; Kisaoglu, A.; Gulaboglu, M.; Yilmaz, I.; Suleyman, H. Protective effect of nimesulide against hepatic ischemia/reperfusion injury in rats: Effects on oxidant/antioxidants, DNA mutation and COX-1/COX-2 levels. Pharmacol. Rep. 2014, 66, 647–652.
170. Bandgar, B.P.; Adsul, L.K.; Chavan, H.V.; Jalde, S.S.; Shringare, S.N.; Shaikh, R.; Meshram, R.J.; Gacche, R.N.; Masand, V. Synthesis, biological evaluation, and docking studies of 3-(substituted)-aryl-5-(9methyl-3-carbazole)-1H-2-pyrazolines as potent anti-inflammatory and antioxidant agents. Bioorg. Med. Chem. Lett. 2012, 22, 5839–5844.
171. Bandgar, B.P.; Chavan, H.V.; Adsul, L.K.; Thakare, V.N.; Shringare, S.N.; Shaikh, R.; Gacche, R.N. Design, synthesis, characterization and biological evaluation of novel pyrazole integrated benzophenones. Bioorg. Med. Chem. Lett. 2013, 23, 912–916.
172. Pontiki, E.; Hadjipavlou-Litina, D.; Litinas, K.; Nicolotti, O.; Carotti, A. Design, synthesis and pharmacobiological evaluation of novel acrylic acid derivatives acting as lipoxygenase and cyclooxygenase-1 inhibitors with antioxidant and anti-inflammatory activities. Eur. J. Med. Chem. 2011, 46, 191–200.
173. Scholz, M.; Ulbrich, H.K.; Soehnlein, O.; Lindbom, L.; Mattern, A.; Dannhardt, G. Diaryl-dithiolanes and -isothiazoles: COX-1/COX-2 and 5-LOX-inhibitory, ‚OH scavenging and anti-adhesive activities. Bioorg. Med. Chem. 2009, 17, 558–568.
174. Ahmad, S.; Israf, D.A.; Lajis, N.H.; Shaari, K.; Mohamed, H.; Wahab, A.A.; Ariffin, K.T.; Hoo, W.Y.; Aziz, N.A.; Kadir, A.A.; et al. Cardamonin, inhibits pro-inflammatory mediators in activated raw 264.7 cells and whole blood. Eur. J. Pharmacol. 2006, 538, 188–194.
175. Sherif, Y.E.-S.; El-Asmy, A.A.-H.; Lotfy, M. 4-hydroxy-2-methyl-N-(2-thiazole)-2H-1,2-benzothiazine3-carboxamide-1,1-dioxide (EX15) and its cu(II) complex as new oxicam selective cyclooxygenase-2 inhibitors. Croat. Chem. Acta 2012, 85, 19–26.
176. Bengmark, S. Curcumin, an atoxic antioxidant and natural NFκB, cyclooxygenase-2, lipooxygenase, and inducible nitric oxide synthase inhibitor: A shield against acute and chronic diseases. JPEN J. Parenter. Enter. Nutr. 2006, 30, 45–51.
177. Bandgar, B.P.; Kinkar, S.N.; Chavan, H.V.; Jalde, S.S.; Shaikh, R.U.; Gacche, R.N. Synthesis and biological evaluation of asymmetric indole curcumin analogs as potential anti-inflammatory and antioxidant agents. J. Enzyme Inhib. Med. Chem. 2014, 29, 7–11.
178. Selvam, C.; Jachak, S.M.; Thilagavathi, R.; Chakraborti, A.K. Design, synthesis, biological evaluation and molecular docking of curcumin analogues as antioxidant, cyclooxygenase inhibitory and anti-inflammatory agents. Bioorg. Med. Chem. Lett. 2005, 15, 1793–1797.
179. Gautam, R.; Jachak, S.M.; Kumar, V.; Mohan, C.G. Synthesis, biological evaluation and molecular docking studies of stellatin derivatives as cyclooxygenase (COX-1, COX-2) inhibitors and anti-inflammatory agents. Bioorg. Med. Chem. Lett. 2011, 21, 1612–1616.
180. Ziakas, G.N.; Rekka, E.A.; Gavalas, A.M.; Eleftheriou, P.T.; Kourounakis, P.N. New analogues of butylated hydroxytoluene as anti-inflammatory and antioxidant agents. Bioorg. Med. Chem. 2006, 14, 5616–5624.
181. Kim, S.; Lee, E.H.; Kim, S.H.; Lee, S.; Lim, S.J. Comparison of three tocopherol analogs as an inhibitor of production of proinflammatory mediators in macrophages. J. Pharmacol. Sci. 2012, 118, 237–244.
182. Candelario-Jalil, E.; de Oliveira, A.C.P.; Graef, S.; Bhatia, H.S.; Huell, M.; Munoz, E.; Fiebich, B.L. Resveratrol potently reduces prostaglandin E2 production and free radical formation in lipopolysaccharide-activated primary rat microglia. J. Neuroinflamm. 2007, 4.
183. Bitto, A.; Squadrito, F.; Irrera, N.; Pizzino, G.; Pallio, G.; Mecchio, A.; Galfo, F.; Altavilla, D. Flavocoxid, a nutraceutical approach to blunt inflammatory conditions. Mediat. Inflamm. 2014, 2014.
184. Hirata, A.; Murakami, Y.; Shoji, M.; Kadoma, Y.; Fujisawa, S. Kinetics of radical-scavenging activity of hesperetin and hesperidin and their inhibitory activity on COX-2 expression. Anticancer Res. 2005, 25, 3367–3374.
185. Seo, K.; Yang, J.H.; Kim, S.C.; Ku, S.K.; Ki, S.H.; Shin, S.M. The antioxidant effects of isorhamnetin contribute to inhibit COX-2 expression in response to inflammation: A potential role of HO-1. Inflammation 2014, 37, 712–722.
186. Nishio, K.; Fukuhara, A.; Omata, Y.; Saito, Y.; Yamaguchi, S.; Kato, H.; Yoshida, Y.; Niki, E. Characterization of novel furan compounds on the basis of their radical scavenging activity and cytoprotective effects against glutamate- and lipopolysaccharide-induced insults. Bioorg. Med. Chem. 2008, 16, 10332–10337.
187. Yang, M.H.; Yoon, K.D.; Chin, Y.-W.; Park, J.H.; Kim, J. Phenolic compounds with radical scavenging and cyclooxygenase-2 (COX-2) inhibitory activities from dioscorea opposita. Bioorg. Med. Chem. 2009, 17, 2689–2694.
188. Jachak, S.M.; Gautam, R.; Selvam, C.; Madhan, H.; Srivastava, A.; Khan, T. Anti-inflammatory, cyclooxygenase inhibitory and antioxidant activities of standardized extracts of tridax procumbens l. Fitoterapia 2011, 82, 173–177.
189. Alves, F.R.D.; Barreiro, E.J.; Fraga, C.A.M. From nature to drug discovery: The indole scaffold as a “privileged structure”. Mini Rev. Med. Chem. 2009, 9, 782–793.
190. Aiello, F.V. Guiseppe. Synthesis and evaluation of indole based molecules for treatment of oxidative stress related diseases. Curr. Top. Med. Chem. 2014, 14, 2576–2589.
191. Hemalatha, K.; Madhumitha, G.; Roopan, S.M. Indole as a core anti-inflammatory agent—A mini review. Chem. Sci. Rev. Lett. 2013, 2, 287–292.
192. Lal, S.; Snape, T.J. 2-Arylindoles: A privileged molecular scaffold with potent, broad-ranging pharmacological activity. Curr. Med. Chem. 2012, 19, 4828–4837.
193. Shirazi, A.; Ghobadi, G.; Ghazi-Khansari, M. A radiobiological review on melatonin: A novel radioprotector. J. Radiat. Res. 2007, 48, 263–272.
194. Tan, D.X.; Manchester, L.C.; Terron, M.P.; Flores, L.J.; Reiter, R.J. One molecule, many derivatives: A never-ending interaction of melatonin with reactive oxygen and nitrogen species? J. Pineal Res. 2007, 42, 28–42.
195. Walters-Laporte, E.; Furman, C.; Fouquet, S.; Martin-Nizard, F.; Lestavel, S.; Gozzo, A.; Lesieur, D.; Fruchart, J.C.; Duriez, P.; Teissier, E. A high concentration of melatonin inhibits in vitro LDL peroxidation but not oxidized LDL toxicity toward cultured endothelial cells. J. Cardiovasc. Pharmacol. 1998, 32, 582–592.
196. Poeggeler, B.; Thuermann, S.; Dose, A.; Schoenke, M.; Burkhardt, S.; Hardeland, R. Melatonin’s unique radical scavenging properties—Roles of its functional substituents as revealed by a comparison with its structural analogs. J. Pineal Res. 2002, 33, 20–30.
197. Mor, M.; Spadoni, G.; Diamantini, G.; Bedini, A.; Tarzia, G.; Silva, C.; Vacondio, F.; Rivara, M.; Plazzi, P.; Franceschinit, D.; et al. Antioxidant and cytoprotective activity of indole derivatives related to melatonin. Adv. Exp. Med. Biol. 2003, 527, 567–575.
198. Gozzo, A.; Lesieur, D.; Duriez, P.; Fruchart, J.C.; Teissier, E. Structure-activity relationships in a series of melatonin analogues with the low-density lipoprotein oxidation model. Free Radic. Biol. Med. 1999, 26, 1538–1543.
199. Lissi, E.A.; Faure, M.; Montoya, N.; Videla, L.A. Reactivity of indole derivatives towards oxygenated radicals. Free Radic. Res. Commun. 1991, 15, 211–222.
200. Tabor, M.W.; Coats, E.; Sainsbury, M.; Shertzer, H.G. Antioxidation potential of indole compounds—Structure activity studies. Adv. Exp. Med. Biol. 1991, 283, 833–836.
201. Suzen, S.; Cihaner, S.S.; Coban, T. Synthesis and comparison of antioxidant properties of indole-based melatonin analogue indole amino acid derivatives. Chem. Biol. Drug Des. 2012, 79, 76–83.
202. Estevão, M.S.; Carvalho, L.C.; Ribeiro, D.; Couto, D.; Freitas, M.; Gomes, A.; Ferreira, L.M.; Fernandes, E.; Marques, M.M.B. Antioxidant activity of unexplored indole derivatives: Synthesis and screening. Eur. J. Med. Chem. 2010, 45, 4869–4878.
203. Aboul-Enein, H.Y.; Kruk, I.; Lichszteld, K.; Michalska, T.; Kladna, A.; Marczynski, S.; Ölgen, S. Scavenging of reactive oxygen species by N-substituted indole-2 and 3-carboxamides. Luminescence 2004, 19, 1–7.
204. Olgen, S.; Coban, T. Synthesis and antioxidant properties of novel N-substituted indole-2-carboxamide and indole-3-acetamide derivatives. Arch. Pharm. 2002, 335, 331–338.
205. Ölgen, S.; Coban, T. Antioxidant activity of n-substituted indole 2- and 3-carboxamides. J. Fac. Pharm Ank. 2004, 33, 109–116.
206. Olgen, S.; Guner, E.; Fabregat, M.A.; Crespo, M.I.; Nebioglu, D. Syntheses and biological evaluation of indole-2 and 3-carboxamides: New selective cyclooxygenase-2 inhibitors. Pharmazie 2002, 57, 238–242.
207. Olgen, S.; Akaho, E.; Nebioglu, D. Synthesis and receptor docking studies of N-substituted indole-2-carboxylic acid esters as a search for COX-2 selective enzyme inhibitors. Eur. J. Med. Chem. 2001, 36, 747–770.
208. Kruk, I.; Aboul-Enein, H.Y.; Michalska, T.; Lichszteld, K.; Kubasik-Kladna, K.; Ölgen, S. In vitro scavenging activity for reactive oxygen species by N-substituted indole-2-carboxylic acid esters. Luminescence 2007, 22, 379–386.
209. Campbell, J.A.; Bordunov, V.; Broka, C.A.; Browner, M.F.; Kress, J.M.; Mirzadegan, T.; Ramesha, C.; Sanpablo, B.F.; Stabler, R.; Takahara, P.; et al. Rational design of 6-methylsulfonylindoles as selective cyclooxygenase-2 inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 4741–4745.
210. Kaur, J.; Bhardwaj, A.; Huang, Z.; Knaus, E.E. N-1 and C-3 substituted indole schiff bases as selective COX-2 inhibitors: Synthesis and biological evaluation. Bioorg. Med. Chem. Lett. 2012, 22, 2154–2159.
211. Estevão, M.S.; Carvalho, L.C.R.; Freitas, M.; Gomes, A.; Viegas, A.; Manso, J.; Erhardt, S.; Fernandes, E.; Cabrita, E.J.; Marques, M.M.B. Indole based cyclooxygenase inhibitors: Synthesis, biological evaluation, docking and NMR screening. Eur. J. Med. Chem. 2012, 54, 823–833.
212. Maffei Facino, R.; Carini, M.; Aldini, G.; Saibene, L.; Macciocchi, A. Antioxidant profile of nimesulide, indomethacin and diclofenac in phosphatidylcholine liposomes (PCL) as membrane model. Int. J. Tissue React. 1993, 15, 225–234.
213. Purpora, R.; Massad, W.; Ferrari, G.; Reynoso, E.; Criado, S.; Miskoski, S.; Pajares, A.; García, N.A. The NSAIDs indomethacin and diflunisal as scavengers of photogenerated reactive oxygen species. Photochem. Photobiol. 2013, 89, 1463–1470.
214. Kalgutkar, A.S.; Crews, B.C.; Rowlinson, S.W.; Marnett, A.B.; Kozak, K.R.; Remmel, R.P.; Marnett, L.J. Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: Facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors. Proc. Natl. Acad. Sci. USA 2000, 97, 925–930.
215. Kalgutkar, A.S.; Marnett, A.B.; Crews, B.C.; Remmel, R.P.; Marnett, L.J. Ester and amide derivatives of the nonsteroidal antiinflammatory drug, indomethacin, as selective cyclooxygenase-2 inhibitors. J. Med. Chem. 2000, 43, 2860–2870.
216. Kalgutkar, A.S.; Crews, B.C.; Saleh, S.; Prudhomme, D.; Marnett, L.J. Indolyl esters and amides related to indomethacin are selective COX-2 inhibitors. Bioorg. Med. Chem. 2005, 13, 6810–6822.
217. Uddin, M.J.; Crews, B.C.; Ghebreselasie, K.; Marnett, L.J. Design, synthesis, and structure–activity relationship studies of fluorescent inhibitors of cycloxygenase-2 as targeted optical imaging agents. Bioconjug. Chem. 2013, 24, 712–723.
218. Scholz, M.; Blobaum, A.L.; Marnett, L.J.; Hey-Hawkins, E. Ortho-carbaborane derivatives of indomethacin as cyclooxygenase (COX)-2 selective inhibitors. Bioorg. Med. Chem. 2012, 20, 4830–4837.
219. Uddin, M.J.; Crews, B.C.; Blobaum, A.L.; Kingsley, P.J.; Gorden, D.L.; McIntyre, J.O.; Matrisian, L.M.; Subbaramaiah, K.; Dannenberg, A.J.; Piston, D.W.; et al. Selective visualization of cyclooxygenase-2 in inflammation and cancer by targeted fluorescent imaging agents. Cancer Res. 2010, 70, 3618–3627.
220. Neumann, W.; Xu, S.; Sarosi, M.B.; Scholz, M.S.; Crews, B.C.; Ghebreselasie, K.; Banerjee, S.; Marnett, L.J.; Hey-Hawkins, H.C. Nido-dicarbaborate induces potent and selective inhibition of cyclooxygenase-2. ChemMedChem 2015, 11, 175–178.
221. Uddin, M.J.; Crews, B.C.; Huda, I.; Ghebreselasie, K.; Daniel, C.K.; Marnett, L.J. Trifluoromethyl fluorocoxib a detects cyclooxygenase-2 expression in inflammatory tissues and human tumor xenografts. ACS Med. Chem. Lett. 2014, 5, 446–450.
222. Black, W.C.; Bayly, C.; Belley, M.; Chan, C.C.; Charleson, S.; Denis, D.; Gauthier, J.Y.; Gordon, R.; Guay, D.; Kargman, S.; et al. From indomethacin to a selective COX-2 inhibitor: Development of indolalkanoic acids as potent and selective cyclooxygenase-2 inhibitors. Bioorg. Med. Chem. Lett. 1996, 6, 725–730.
223. Blobaum, A.L.; Uddin, M.J.; Felts, A.S.; Crews, B.C.; Rouzer, C.A.; Marnett, L.J. The 21 -trifluoromethyl analogue of indomethacin is a potent and selective COX-2 inhibitor. ACS Med. Chem. Lett. 2013, 4, 486–490.
224. Zarghi, A. Design and synthesis of some 5-substituted-2-(4-(azido or methylsulfonyl)phenyl)-1H-indole derivatives as selective cyclooxygenase (COX-2) inhibitors. Sci. Pharm. 2008, 76, 361–376.
225. Laube, M.; Neumann, W.; Scholz, M.; Lonnecke, P.; Crews, B.; Marnett, L.J.; Pietzsch, J.; Kniess, T.; Hey-Hawkins, E. 2-Carbaborane-3-phenyl-1H-indoles—Synthesis via McMurry reaction and cyclooxygenase (COX) inhibition activity. ChemMedChem 2013, 8, 329–335.
226. van der Veen, S.J.; Ghobadi, G.; de Boer, R.A.; Faber, H.; Cannon, M.V.; Nagle, P.W.; Brandenburg, S.; Langendijk, J.A.; van Luijk, P.; Coppes, R.P. Ace inhibition attenuates radiation-induced cardiopulmonary damage. Radiother. Oncol. 2015, 114, 96–103.
227. Mahmood, J.; Jelveh, S.; Zaidi, A.; Doctrow, S.R.; Medhora, M.; Hill, R.P. Targeting the renin-angiotensin system combined with an antioxidant is highly effective in mitigating radiation-induced lung damage. Int. J. Radiat. Oncol. Biol. Phys. 2014, 89, 722–728.
228. Bechmann, N.; Kniess, T.; Kockerling, M.; Pigorsch, A.; Steinbach, J.; Pietzsch, J. Novel (pyrazolyl) benzenesulfonamides with a nitric oxide-releasing moiety as selective cyclooxygenase-2 inhibitors. Bioorg. Med. Chem. Lett. 2015, 25, 3295–3300.
229. Huerta, S. Nitric oxide for cancer therapy. Future Sci. OA 2015, 1, FSO44.